PD42-06 BOOSTING THE COMBINATION OF RADIATION AND ANTI-PD-L1 WITH STING AGONIST IN A PRECLINICAL MUSCLE INVASIVE BLADDER CANCER MURINE MODEL

You have accessJournal of UrologyBladder Cancer: Basic Research & Pathophysiology II (PD42)1 Sep 2021PD42-06 BOOSTING THE COMBINATION OF RADIATION AND ANTI-PD-L1 WITH STING AGONIST IN A PRECLINICAL MUSCLE INVASIVE BLADDER CANCER MURINE MODEL Gautier Marcq, Jiamin Huang, Côme Tholomier, Surashri Shinde-Jadhav, Ronald Kool, Rodrigo Skowronski, Fadi Brimo, Jose Joao Mansure, and Wassim Kassouf MarcqGautier Marcq More articles by this author , HuangJiamin Huang TholomierCôme Tholomier Shinde-JadhavSurashri Shinde-Jadhav KoolRonald Kool SkowronskiRodrigo Skowronski BrimoFadi Brimo MansureJose Mansure KassoufWassim View All Author Informationhttps://doi.org/10.1097/JU.0000000000002056.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION OBJECTIVE: To evaluate the efficacy a agonist in combination radiation therapy (RT) with anti-PDL-1 preclinical muscle invasive bladder cancer (MIBC) murine model. METHODS: syngeneic model was used. MB49 MIBC cell line injected (5.105 cells/200 uL) subcutaneously (s.c.) both flanks C57BL/6. When tumors reached 0.15 cm3, mice were randomly assigned each following 8 groups (10 mice⁄group): (1) Control; (2) alone; (3) RT alone (2 fractions 6.25Gy right flank); (4) + agonist; (5) anti-PD-L1 (6) anti-PD-L1; (7) (8) anti-PD-L1. Tumor volume 1.5 cm3 used as primary endpoint. Mice monitored daily for 4 weeks. ANOVA repeated measures assess differences tumor growth. microenvironment (TME) analyzed flow cytometry. RESULTS: The showed significantly better anti-tumor activity than control group (p<0.001). addition improved response treatment (p=0.0007). Finally, combined anti-PD-L1also (p<0.0001). Concerning non-irradiated abscopal site, enhanced (p<0.001) treatments maximal seen triple (RT, agonist, anti-PD-L1, p<0.001). TME analysis revealed higher CD8 infiltration arms including immunosuppressive profile (Figure). CONCLUSIONS: Activation pathway boosts within irradiated sites. Source Funding: Canadian Institutes Health PD42-06 © 2021 American Urological Association Education Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e726-e726 Advertisement Copyright Permissions© Inc.MetricsAuthor Information Expand Loading ...